Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease

David S. Knopman

doi:10.1016/j.jalz.2006.10.002

Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease

David S. Knopman

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	21-22
Number of pages	2
Journal	Alzheimer's and Dementia
Volume	3
Issue number	1
DOIs	https://doi.org/10.1016/j.jalz.2006.10.002
State	Published - Jan 2007

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.jalz.2006.10.002

Cite this

@article{93fd0051fed543e2907c3ff50ab63845,

title = "Commentary on {"}Meta-analysis of six-month memantine trials in Alzheimer's disease.{"} Memantine has negligible benefits in mild to moderate Alzheimer's disease",

author = "Knopman, {David S.}",

year = "2007",

month = jan,

doi = "10.1016/j.jalz.2006.10.002",

language = "English (US)",

volume = "3",

pages = "21--22",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease

AU - Knopman, David S.

PY - 2007/1

Y1 - 2007/1

UR - http://www.scopus.com/inward/record.url?scp=33846125247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846125247&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2006.10.002

DO - 10.1016/j.jalz.2006.10.002

M3 - Comment/debate

C2 - 19595912

AN - SCOPUS:33846125247

VL - 3

SP - 21

EP - 22

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 1

ER -

Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this